Home › T-Cell Lymphoma › Minnesota
T-Cell Lymphoma clinical trials in Minnesota
9 studies for T-Cell Lymphoma are looking for participants at sites in Minnesota.
Cities in Minnesota
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Essentia Health Cancer Center, Duluth
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04803201Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 14, 2026 · NCT06724237Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 75 · All sexes · Updated Jul 6, 2026 · NCT05805605Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06508463A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT03017820A Registry for People With T-cell Lymphoma
- Mayo Clinic (Data Collection Only), Rochester
RecruitingObservational study
All ages · All sexes · Updated May 20, 2026 · NCT05978141Auto Stem Cell Transplant for Lymphoma Patients
- Masonic Cancer Center, University of Minnesota, Minneapolis
RecruitingPhase 2
Up to age 75 · All sexes · Updated Nov 4, 2025 · NCT03125642Q702 for the Treatment of Patients With Hematologic Malignancies
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 10, 2025 · NCT06712810Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital and Clinics of Minnesota, Minneapolis
RecruitingPhase 1
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.